Kalaris Therapeutics, Inc. (KLRS)Healthcare | Biotechnology | Berkeley Heights, United States | NasdaqGM
6.32 USD
-0.27
(-4.097%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 6.45 +0.13 (2.057%) ⇧ (April 17, 2026, 7:29 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 6:37 p.m. EDT
KLRS presents a classic biotech volatility trap: strong short-term technical momentum driven by institutional accumulation and a recent 24% surge, yet fundamentally anchored by zero dividends, massive cash burn, and dilutive capital raises. While the current price is rebuilding above the 200-day moving average with bullish analyst targets, the forecasting model's extreme heteroscedasticity and near-zero predictive drift signal high noise, suggesting this is a speculative momentum play rather than a trend. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.217139 |
| AutoETS | 0.218766 |
| AutoTheta | 0.520706 |
| AutoARIMA | 0.553915 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 26.94 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.095 |
| Excess Kurtosis | -1.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.837 |
| Market Cap | 144,906,880 |
| Forward P/E | -4.17 |
| Website | https://kalaristx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.043872893 |
| Address1 | 400 Connell Drive |
| Address2 | Suite 5500 Berkeley Heights |
| All Time High | 1,126.08 |
| All Time Low | 2.14 |
| Ask | 6.39 |
| Ask Size | 1 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 113,200 |
| Average Daily Volume3 Month | 66,611 |
| Average Volume | 66,611 |
| Average Volume10Days | 113,200 |
| Bid | 6.14 |
| Bid Size | 1 |
| Book Value | 3.441 |
| City | Berkeley Heights |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.32 |
| Current Ratio | 12.231 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 6.68 |
| Day Low | 6.105 |
| Debt To Equity | 1.837 |
| Display Name | Kalaris Therapeutics |
| Earnings Timestamp End | 1,754,569,800 |
| Earnings Timestamp Start | 1,754,569,800 |
| Ebitda | -46,139,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.615 |
| Enterprise Value | 28,372,874 |
| Eps Current Year | -2.21571 |
| Eps Forward | -1.51714 |
| Eps Trailing Twelve Months | -2.85 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.0948 |
| Fifty Day Average Change | -1.7747998 |
| Fifty Day Average Change Percent | -0.21925184 |
| Fifty Two Week Change Percent | -4.387289 |
| Fifty Two Week High | 11.88 |
| Fifty Two Week High Change | -5.56 |
| Fifty Two Week High Change Percent | -0.46801347 |
| Fifty Two Week Low | 2.14 |
| Fifty Two Week Low Change | 4.1800003 |
| Fifty Two Week Low Change Percent | 1.953271 |
| Fifty Two Week Range | 2.14 - 11.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,596,115,800,000 |
| Float Shares | 6,054,906 |
| Forward Eps | -1.51714 |
| Forward P E | -4.165733 |
| Free Cashflow | -23,187,124 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 20 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10271 |
| Held Percent Institutions | 0.78858 |
| Implied Shares Outstanding | 22,928,303 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,736,985,600 |
| Last Split Factor | 1:23 |
| Long Business Summary | Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey. |
| Long Name | Kalaris Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 144,906,880 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1900954228 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -43,438,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 143,760,459 |
| Number Of Analyst Opinions | 7 |
| Open | 6.68 |
| Operating Cashflow | -38,370,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650-249-2727 |
| Post Market Change | 0.12999964 |
| Post Market Change Percent | 2.0569563 |
| Post Market Price | 6.45 |
| Post Market Time | 1,776,468,561 |
| Previous Close | 6.59 |
| Price Eps Current Year | -2.852359 |
| Price Hint | 2 |
| Price To Book | 1.8366754 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.146 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.57143 |
| Region | US |
| Regular Market Change | -0.27 |
| Regular Market Change Percent | -4.09712 |
| Regular Market Day High | 6.68 |
| Regular Market Day Low | 6.105 |
| Regular Market Day Range | 6.105 - 6.68 |
| Regular Market Open | 6.68 |
| Regular Market Previous Close | 6.59 |
| Regular Market Price | 6.32 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 105,975 |
| Return On Assets | -0.45106 |
| Return On Equity | -3.0810401 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 22,928,303 |
| Shares Percent Shares Out | 0.0434 |
| Shares Short | 995,274 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 896,832 |
| Short Name | Kalaris Therapeutics, Inc. |
| Short Percent Of Float | 0.111099996 |
| Short Ratio | 16.67 |
| Source Interval | 15 |
| State | NJ |
| Symbol | KLRS |
| Target High Price | 27.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 19.42857 |
| Target Median Price | 20.0 |
| Total Cash | 117,982,000 |
| Total Cash Per Share | 5.146 |
| Total Debt | 1,448,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.85 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.16795 |
| Two Hundred Day Average Change | 0.15205002 |
| Two Hundred Day Average Change Percent | 0.024651628 |
| Type Disp | Equity |
| Volume | 105,975 |
| Website | https://kalaristx.com |
| Zip | 7,922 |